K13V

K13V is a preclinical gene therapy candidate developed by Primary Peptides for the treatment of vascular dementia and the mitigation of stroke-induced brain damage. The therapeutic consists of a stroke-triggered gene vector designed to express and release the K13 peptide specifically in response to a stroke event. The K13 peptide functions by blocking the protein-protein interaction between Phosphatase and tensin homolog (PTEN) and the E3 ubiquitin ligase NEDD4. By preventing this interaction, K13V aims to mitigate the pathological signaling cascade that leads to neuronal death, thereby reducing the cognitive and physical impairments associated with ischemic stroke and vascular dementia.

Other names

K13 peptideK-13 peptideK 13 peptide